Recent advances in the development of P-gp inhibitors

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Oncology

Background:

• Multidrug resistance (MDR) significantly compromises anti-cancer therapy efficacy.
• Overexpression of drug-efflux pumps, notably P-glycoprotein (P-gp), reduces intracellular drug concentrations.
• P-gp actively extrudes cytostatic agents, leading to treatment failure in previously sensitive cancer cells.

Purpose of the Study:

• To review recent advancements in the development of P-glycoprotein (P-gp) inhibitors.
• To analyze structure-activity relationships (SAR) across various compound classes targeting P-gp.
• To document improvements in P-gp inhibitor design for overcoming MDR in cancer treatment.

Main Methods:

• Literature review focusing on P-gp inhibitor research.
• Analysis of structure-activity relationships (SAR) for different inhibitor classes.
• Evaluation of reported cytotoxic properties and undesired activities of P-gp inhibitors.

Main Results:

• Significant progress has been made in reducing the inherent cytotoxic properties of P-gp inhibitors.
• Compound classes derived from existing pharmacologically active drugs show reduced undesired activities.
• Structure-activity relationship studies have guided the optimization of P-gp inhibitor efficacy.

Conclusions:

• P-gp inhibitors represent a promising strategy to overcome MDR in cancer therapy.
• Optimized P-gp inhibitors have demonstrated reduced toxicity and improved therapeutic potential.
• Further research is needed to address challenges related to drug interactions and limited in vivo activity.